CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
This article was originally published in The Pink Sheet Daily
Executive Summary
CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.
You may also be interested in...
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research
CytRx Picks Up Four Clinical-Stage Oncology Candidates With Innovive Acquisition
Biopharma separately plans additional toxicology tests for ALS candidate arimoclomal to address clinical hold imposed by FDA.
R&D In Brief
Lacosamide Phase III diabetic neuropathic pain results: UCB's Phase III trial of Vimpat (lacosamide) for treatment of diabetic neuropathic pain met its primary endpoint of sustained reduction in average daily pain scores, firm announces Dec. 11. The randomized, double-blind, placebo-controlled trial in 551 patients showed that the change in the average daily pain was significantly greater with lacosamide 400 mg per day given in standard titration than placebo (p=0.0410). The trial was designed to evaluate lacosamide in two different titration schemes: a standard titration regimen in which patients reached their target dose at day 22, and a fast titration scheme in which the target dose was reached at day eight. The change in pain score with the fast titration regimen was numerically better than placebo, but not statistically significant (p=0.2902). The median time to achieve pain relief was 10 and 11 days for the lacosamide standard and fast titration regimens, respectively, compared with 31 days for placebo. The sodium channel/CRMP-2 agent is under review at FDA with a user fee goal date of July 29, 2008...